Aarti Drugs Limited

Greenhouse gas emissions & sustainability report data

📊 Latest report period: 2023-04 to 2024-03🗂️ Report periods on file: 2023-04 to 2024-03

In its 2023-04 to 2024-03 reporting, Aarti Drugs Limited disclosed greenhouse gas emissions of 135.1K tCO2e/year. By scope: Scope 1: 54.8K tCO2e/year; Scope 2: 80.3K tCO2e/year. Figures are as stated in the company's own report and may use different boundaries, units or methods (for example market-based vs location-based Scope 2), so compare with care.

💨
GHG Emissions
135.1K tCO2e/year
2023-04 to 2024-03
💧
Water Usage
425.4K m3/year
2023-04 to 2024-03
♻️
Waste
40.4K tons/year
2023-04 to 2024-03
⚙️
Energy Use
1.5M GJ/year
2023-04 to 2024-03

📊 Emissions by Scope (2023-04 to 2024-03)

ScopeWhat it coversReported value
Scope 1Direct emissions from sources the company owns or controls (fuel combustion, company vehicles, process and fugitive emissions).54.8K tCO2e/year
Scope 2Indirect emissions from purchased electricity, steam, heat and cooling.80.3K tCO2e/year

New to scopes? Read Scope 1, 2 and 3 emissions explained and market-based vs location-based Scope 2.

✅ Reported Environmental Achievements

🎯 Climate & Sustainability Targets

📅 Medium-term

  • Reduce energy intensity per kg of physical output at all manufacturing sites by 30% by 2030 with respect to 2020
  • Reduce water consumption at site by 30% by 2030 with respect to 2020
  • Reduce waste generation at all sites by 30% by 2030 with respect to 2020
  • Increase productivity at all sites by 20% by 2030 with respect to 2020
  • Reduce scope 1 & scope 2 at all sites by 50% by 2030 with respect to 2020

🌱 ESG Focus Areas

Climate Change, Energy & Emission ManagementCorporate GovernanceWaste and hazardous materials managementRegulatory ComplianceSustainable Supply Chain & Responsible ProcurementBusiness EthicsOccupational Health & SafetyData Privacy & IntegrityWater and wastewater managementEconomic PerformanceCommunity Impact, Relations, and DevelopmentProduct SafetyRisk Management

⚠️ Challenges & Risks +

  • Stringent pharmacopoeia standards
  • Reduced competition due to exit of small manufacturers
  • Stringent compliance requirements for new entrants
  • Global economic uncertainties and sector-specific challenges
  • Climate-related manufacturing losses

📋 Report Information

Reporting Period: 2023-04 to 2024-03
Frameworks: GRI 2021, SASB, UN SDGs, UNGC
Assurance: BDO India LLP